VENTAIRE Drug Patent Profile
✉ Email this page to a colleague
When do Ventaire patents expire, and when can generic versions of Ventaire launch?
Ventaire is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in VENTAIRE is protokylol hydrochloride. Additional details are available on the protokylol hydrochloride profile page.
Summary for VENTAIRE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 24 |
Patent Applications: | 814 |
DailyMed Link: | VENTAIRE at DailyMed |
US Patents and Regulatory Information for VENTAIRE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | VENTAIRE | protokylol hydrochloride | TABLET;ORAL | 083459-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |